SchizophreniaHealthy VolunteersAyahuascaPsilocybin

Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively

This placebo-controlled, double-blind, cross-over, within-subjects study (n=18) investigated whether ayahuasca (42 & 59.5mg/70kg DMT) impairs the ability to filter out unnecessary sensory information in healthy volunteers. This yielded mixed results, with evidence to support that ayahuasca impairs sensorimotor gating in the domain of auditory suppression, but not within the domain of visual-induced prepulse inhibition of the startle reflex.

Authors

  • Jordi Riba
  • Maria Barbanoj

Published

Psychopharmacology
individual Study

Abstract

Rationale

Ayahuasca, a South American psychotropic plant tea, combines the psychedelic agent and 5-HT(2A/2C) agonist N, N-dimethyltryptamine (DMT) with beta-carboline alkaloids showing monoamine oxidase-inhibiting properties. Current human research with psychedelics and entactogens has explored the possibility that drugs displaying agonist activity at the 5-HT(2A/2C) sites temporally disrupt inhibitory neural mechanisms thought to intervene in the normal filtering of information. Suppression of the P50 auditory evoked potential (AEP) and prepulse inhibition of startle (PPI) are considered operational measures of sensory (P50 suppression) and sensorimotor (PPI) gating. Contrary to findings in lower animals, unexpected increases in sensorimotor gating have been found in humans following the administration of the serotonergic psychedelic psilocybin and the serotonin releaser 3,4-methylenedioxymethamphetamine (MDMA). In addition, to our knowledge P50 suppression has not been assessed previously in humans following the administration of a 5-HT(2A/2C) agonist.

Objectives

To assess the effects of the acute administration of ayahuasca on P50 suppression and PPI in humans, in order to evaluate the drug's modulatory actions on these measures of sensory and sensorimotor gating.

Methods

Eighteen healthy volunteers with prior experience of psychedelic drug use participated in a clinical trial in which placebo or ayahuasca doses (0.6 mg and 0.85 mg DMT/kg body weight) were administered according to a double-blind, cross-over balanced design. P50 and startle reflex (pulse-alone and 60 ms, 120 ms, 240 ms and 2000 ms prepulse-to-pulse intervals) recordings were undertaken at 1.5 h and 2 h after drug intake, respectively.

Results

Ayahuasca produced diverging effects on each of the two gating measures evaluated. Whereas significant dose-dependent reductions of P50 suppression were observed after ayahuasca, no significant effects were found on the startle response, its habituation rate, or on PPI at any of the prepulse-to-pulse intervals studied.

Conclusion

The present findings indicate, at the doses tested, a decremental effect of ayahuasca on sensory gating, as measured by P50 suppression, and no distinct effects on sensorimotor gating, as measured by PPI.

Available with Blossom Pro

Research Summary of 'Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively'

Introduction

Ayahuasca is a traditional Amazonian plant brew that combines the psychedelic N,N-dimethyltryptamine (DMT), a 5-HT2A/2C agonist, with beta-carboline alkaloids that inhibit monoamine oxidase (MAO), thereby enabling oral activity of DMT. Earlier research has suggested that serotonergic psychedelics, dopaminergic agonists and NMDA antagonists can transiently alter neural mechanisms that normally filter sensory information. Two operational neurophysiological measures of such gating are suppression of the P50 auditory evoked potential (P50 suppression), taken as an index of sensory gating with hippocampal involvement, and prepulse inhibition of the startle reflex (PPI), an index of sensorimotor gating modulated by a forebrain–brainstem circuit. Prior human pharmacological challenge studies had examined PPI after some serotonergic drugs but, according to the authors, P50 suppression had not been previously assessed in humans following a 5-HT2A/2C agonist challenge. Riba and colleagues set out to evaluate the acute effects of ayahuasca on both P50 suppression and PPI in a single sample of healthy volunteers. The study aimed to determine whether ayahuasca would differentially modulate sensory versus sensorimotor gating and to relate any neurophysiological changes to the subjective psychedelic experience induced by the beverage.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (3)

Papers cited by this study that are also in Blossom

Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers

Riba, J., Anderer, P., Morte, A. et al. · British Journal of Clinical Pharmacology (2002)

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)

Cited By (21)

Papers in Blossom that reference this study

The Altered States Database: Psychometric data from a systematic literature review

Prugger, J., Derdiyok, E., Dinkelacker, J. et al. · Scientific Data (2022)

Scoping Review of Experiential Measures from Psychedelic Research and Clinical Trials

Herrmann, Z., Earleywine, M., De Leo, J. et al. · Journal of Psychoactive Drugs (2022)

Classic Psychedelic Drugs: Update on Biological Mechanisms

Vollenweider, F. X., Smallridge, J. W. · Pharmacopsychiatry (2022)

71 cited
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action

Rieser, N. M., Herdener, M. ;., Preller, K. H. · Current Topics in Behavioral Neurosciences (2021)

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)

Phenomenology, Structure, and Dynamic of Psychedelic States

Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Show all 21 papers
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking

Kuypers, K. P. C., Riba, &. J., De La Fuente Revenga, &. M. et al. · Psychopharmacology (2016)

Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

Valle, M., Maqueda, A. E., Rabella, M. et al. · European Neuropsychopharmacology (2016)

145 cited
New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations

Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)

Acute effects of lysergic acid diethylamide in healthy subjects

Schmid, Y., Enzler, F., Gasser, P. et al. · Biological Psychiatry (2015)

Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans

Maqueda, A. E., Valle, M., Addy, P. H. et al. · International Journal of Neuropsychopharmacology (2015)

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Halberstadt, A. L., Geyer, M. A. · Neuropharmacology (2011)

Serotonin and serotonin receptors in hallucinogen action

Halberstadt, A. L., Nicholas, C. R. · Handbook of Behavioral Neuroscience (2010)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.